CapitalBio

On September 30, 2000, CapitalBio Group Co., Ltd. (also known as the Beijing National Engineering Research Center for Biochips, abbreviated as CapitalBio) was registered and established with the strong support of the State Council, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health, and the Beijing Municipal Government. Initially relying on Tsinghua University, it was jointly established with Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, and the Academy of Military Medical Sciences. It is now affiliated with Sichuan Energy Investment Group Co., Ltd. and is a state-owned innovative high-tech enterprise in China's healthcare industry, as well as a biochip engineering research center operated in an enterprise manner. The group is headquartered in Zhongguancun Life Science Park, Changping District, Beijing, with a registered capital of 409,818,300 RMB and over 2,000 employees. It has R&D, production, operation, and service bases covering more than 100,000 square meters, with R&D centers and large-scale industrialization bases in Beijing, Shanghai, Chongqing, Chengdu, and Dongguan. As of 2021, it has achieved cumulative revenue exceeding 11 billion RMB.

CapitalBio uses biochips as its core technology platform, possessing a complete medical industry chain integrating R&D, production, and sales of clinical diagnostic products, as well as national third-party independent medical laboratory services. In response to the national health policy of "prevention first, integrating traditional Chinese and Western medicine," the company closely combines modern life sciences, biomedical engineering, and artificial intelligence technology with traditional Chinese medicine. By engineering and scientifically upgrading traditional Chinese medicine, it has developed a comprehensive health industry segment covering health products, health management, rehabilitation, and elderly care.

Relying on the strong R&D capabilities of the five research institutes under the Beijing National Engineering Research Center for Biochips (Mobile Wearable Research Institute, Rehabilitation Engineering Research Institute, Health Science Research Institute, Health Technology Research Institute, and Bioinformatics Research Institute), the company has strategically focused on clinical medicine, and then expanded to preventive medicine and rehabilitation medicine. It has established four major industrialization platforms: Western drug R&D, Western medicine diagnostics, traditional Chinese medicine (TCM) R&D, and TCM diagnostics (in preparation), continuously driving innovation and transformation of scientific achievements. In the field of Western drug R&D, CapitalBio, as the largest shareholder, initiated the establishment of Shenzhen Chipscreen Biosciences Co., Ltd., which successfully went public on the STAR Market in 2019 as a pharmaceutical enterprise, setting a record on the STAR Market with an IPO price-to-earnings ratio of 467.51 times. In the field of Western medicine diagnostics, it owns a core second-level holding enterprise, Beijing CapitalBio Technology Co., Ltd., which has consistently maintained a leading position in the domestic biochip and gene detection field, was recognized as a national unicorn enterprise, and is currently advancing its capital operation. In the TCM industry segment, it has a second-level enterprise, Beijing CapitalBio Jingfang Biotechnology Co., Ltd., which focuses on the R&D of innovative TCM drugs and TCM efficacy analysis services. Using its unique molecular Materia Medica database and Molecular Materia Medica AI prescription system as a foundation, the company conducts innovative TCM drug R&D and efficacy analysis in a digital, standardized, and normalized manner, aiming to create a new scientific development path for the modernization and internationalization of TCM.

As one of the first pilot units for third-party individualized medical testing approved by the National Health and Family Planning Commission, CapitalBio is also among the first batch of pilot units for clinical application of high-throughput gene sequencing technology in genetic disease diagnosis, prenatal screening and diagnosis, preimplantation genetic diagnosis, and tumor diagnosis and treatment. It is also one of the most qualified units in this field. The company has established over 20 independent medical laboratory branches across various provinces, cities, and autonomous regions, and has won the construction task for 23 centers in the national competition for the construction of 35 "National Gene Testing Technology Application Demonstration Centers" approved by the National Development and Reform Commission, making it a major force among national gene testing demonstration centers.

Over the past two decades since its establishment, CapitalBio has successfully developed dozens of products and services with independent intellectual property rights for clinical diagnosis and health management both domestically and internationally. To date, the company has obtained over 480 authorized patents globally, with a patent conversion rate exceeding 50%. As the chairman unit and secretariat of the National Biochip Standardization Committee, the company has led the formulation and issuance of 17 national standards and 8 industry standards. In 2007, the project "Development and Application of Systematic Biochips and Related Instruments" won the second prize of the National Technological Invention Award. Ten years later, in 2018, the project "Development and Application of Hereditary Deafness Gene Diagnostic Chip System" won the second prize of the National Technological Invention Award again, demonstrating the company's strong scientific research capabilities. In terms of scientific research services, CapitalBio has supported clinical and research users in publishing over 2,000 papers in internationally renowned journals such as Science, Cell, Nature, Nature Genetics, and Nature Biotechnology, with a cumulative impact factor exceeding 10,000.

Owing to its excellent R&D, production, marketing, and service teams, as well as its internationally leading biochip technology platform and high-standard quality assurance system, CapitalBio has not only established strategic partnerships with nearly 100 well-known top-tier hospitals, medical universities, and public security and judicial institutions in China, but has also built relationships with internationally renowned life science and medical diagnostics companies such as Roche Applied Science, Roche Diagnostics, and Thermo Fisher. This has broken the long-standing foreign monopoly on biochips and supporting production equipment and analytical instruments, enabling the export of 'Created in China' biotechnology products to over 30 countries and regions, including Europe, the United States, and Japan. In the inheritance, innovation, and development of traditional Chinese medicine, CapitalBio, through 'interpreting TCM with Western science,' has established a molecular version of the 'Compendium of Materia Medica' to explore the molecular functions and scientific connotations of Chinese herbal medicines. It is also continuously exploring the modernization and engineering of TCM instruments, promoting the 'integrity and innovation' of TCM to go global. After years of efforts, CapitalBio has laid a solid technical foundation for the development of China's bioindustry and has provided significant scientific and technological support for the scientific, standardized, and digital development of TCM.